ArticleTranslational psychiatry2026
Effects of methylphenidate on the human vascular endothelium.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Methylphenidate (MPH) is a widely used psychostimulant for treating attention-deficit/hyperactivity disorder (ADHD). Emerging epidemiological findings suggest that MPH treatment increases the risk of cardiovascular events. However, as causality could not be inferred, further investigation of the potential impact of MPH on human vascular endothelial function is warranted. We investigated the effects of MPH on human brain microvascular endothelial cells (HBEC) and human aortic endothelial cells (HAEC) across a range of concentrations, including those corresponding to therapeutic plasma levels, at 24 and 48 h. Gene expression profiling of twenty-nine endothelial function-related genes was performed. Protein expression was assessed by ELISA, Western blotting, immunofluorescence and FACS, and barrier function was evaluated using FITC-dextran permeability and electric cell-substrate impedance sensing assays. Key endothelial markers with differential levels were analysed also in plasma from ADHD children (n = 87) and adults (n = 102), and matched controls (n = 4 and n = 44, respectively). Exposure to MPH altered levels of several endothelial function-related genes. Across all concentrations tested, MPH increased the secretion of von Willebrand factor (vWF) and tissue plasminogen activator, whereas supratherapeutic concentrations 50 µM and/or 100 µM MPH decreased Claudin-5 expression and impaired endothelial barrier integrity. In clinical plasma samples, children receiving MPH showed higher vWF levels compared with medication-naïve children, but this was not observed in adult samples. Our findings suggest that acute exposure to therapeutic MPH concentration was associated with endothelial activation, and that supratherapeutic concentrations (50 µM and/or 100 µM) may further compromise barrier integrity. These experimental outcomes may propose potential effects on vascular health associated with MPH use. Further studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.